Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osocimab monthly subcutaneous dosing in hemodialysis patients with end-stage kidney disease
MOH_2020-09-17_009251Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of osocimab in thromboembolism (4 arms), sponsored by Bayer. Primary endpoint: Primary endpoint not reported. Started Sep 2020; status: active, not recruiting.
02
Drugs
osocimab
03
Conditions
thromboembolism
Beyond the preview
Go deeper on MOH_2020-09-17_009251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-17_009251.